| 1 |
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer
|
27 Dec 2008 |
30,125 |
| 2 |
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
N.K. Aaronson, Sam Hjelmeland Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute
|
3 Mar 1993 |
16,252 |
| 3 |
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute
|
2 Feb 2000 |
15,773 |
| 4 |
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Thomas James Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine
|
19 May 2004 |
11,595 |
| 5 |
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team · New England Journal of Medicine
Open access |
29 Jun 2011 |
11,266 |
| 6 |
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein, Eric A Collisson, Gordon Brent Mills et al. · Nature Genetics
Open access |
26 Sep 2013 |
9,847 |
| 7 |
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Guillermo Paez, Pasi Antero Janne, Jeffrey C. Lee et al. · Science
|
3 May 2004 |
9,471 |
| 8 |
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie Renee Brahmer et al. · New England Journal of Medicine
Open access |
31 May 2015 |
8,632 |
| 9 |
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony S.K. Mok, Yi-Long Lung Cancer Wu, Sumitra Thongprasert et al. · New England Journal of Medicine
Open access |
19 Aug 2009 |
8,331 |
| 10 |
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi et al. · Science
Open access |
12 Mar 2015 |
8,049 |
| 11 |
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi et al. · New England Journal of Medicine
Open access |
16 Apr 2018 |
6,764 |
| 12 |
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging
Mahul B. Amin, Frederick L. Greene, Stephen B. Edge et al. · CA A Cancer Journal for Clinicians
Open access |
17 Jan 2017 |
6,689 |
| 13 |
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]
NL Harris, ES Jaffe, H Stein et al. · Blood
Open access |
Sep 1994 |
6,356 |
| 14 |
Cancer treatment and survivorship statistics, 2016
Kimberly D. Miller, Rebecca L. Siegel, Chun Chieh Lin et al. · CA A Cancer Journal for Clinicians
Open access |
2 Jun 2016 |
6,175 |
| 15 |
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al. · Nature
Open access310 authors |
8 Jul 2014 |
5,968 |
| 16 |
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine
Open access |
13 Dec 2006 |
5,802 |
| 17 |
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo et al. · New England Journal of Medicine
|
23 Jun 2010 |
5,607 |
| 18 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al. · The Lancet Oncology
Open access |
30 Jan 2012 |
5,563 |
| 19 |
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature
|
11 Jul 2007 |
5,494 |
| 20 |
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
Pornpimol Charoentong, Francesca Finotello, Mihaela Angelova et al. · Cell Reports
Open access |
2017 |
5,483 |
| 21 |
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria et al. · New England Journal of Medicine
Open access |
18 Nov 2017 |
5,475 |
| 22 |
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Frances Alice Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine
Open access |
13 Jul 2005 |
5,471 |
| 23 |
A New Initiative on Precision Medicine
Francis S. Collins, HAROLD E. VARMUS · New England Journal of Medicine
Open access |
30 Jan 2015 |
5,301 |
| 24 |
The biology and management of non-small cell lung cancer
Roy S. Herbst, Daniel Morgensztern, CHRIS H. BOSHOFF · Nature
|
2018 |
5,116 |
| 25 |
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Joan H. Schiller, David T. Harrington, Chandra Prakash Belani et al. · New England Journal of Medicine
|
10 Jan 2002 |
5,010 |
| 26 |
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William David Travis et al. · Journal of Thoracic Oncology
Open access |
20 Jan 2011 |
4,890 |
| 27 |
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw et al. · Journal of Thoracic Oncology
Open access152 authors |
2016 |
4,749 |
| 28 |
Cancer drug resistance: an evolving paradigm
Caitriona Holohan, Sandra Van Schaeybroeck, Daniel B. Longley et al. · Nature reviews. Cancer
Review |
24 Sep 2013 |
4,739 |
| 29 |
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al. · New England Journal of Medicine
Open access |
18 May 2014 |
4,731 |
| 30 |
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Joseph Antonia et al. · New England Journal of Medicine
Open access |
8 Sep 2017 |
4,653 |
| 31 |
Revisions in the International System for Staging Lung Cancer
Clifton F. Mountain · CHEST Journal
|
Jun 1997 |
4,608 |
| 32 |
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice Lee Kwak et al. · New England Journal of Medicine
Open access |
27 Oct 2010 |
4,517 |
| 33 |
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science
|
26 Apr 2007 |
4,504 |
| 34 |
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al. · Nature Genetics
Open access |
8 Jan 2019 |
4,458 |
| 35 |
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Wanjuan Yang, Jorge Soares, Patricia Greninger et al. · Nucleic Acids Research
Open access |
22 Nov 2012 |
4,422 |
| 36 |
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
William J. Pao, Vincent A. Miller, Maureen Frances Zakowski et al. · Proceedings of the National Academy of Sciences
Open access |
25 Aug 2004 |
4,369 |
| 37 |
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al. · The Lancet Oncology
|
19 Dec 2009 |
4,130 |
| 38 |
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al. · The Lancet Oncology
|
25 Jul 2011 |
4,126 |
| 39 |
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al. · Nature
Open access339 authors |
7 Sep 2012 |
4,071 |
| 40 |
High Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced CT in a Rapid Outpatient Diagnostic Program for Patients with Suspected Lung Cancer
Pepijn Brocken, Henricus F.M. van der Heijden, P.N.R. Dekhuijzen et al. · Respiration
Open access |
16 Apr 2013 |
4,004 |
| 41 |
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Susumu S. Kobayashi, Titus J. Boggon, Tajhal Dayaram et al. · New England Journal of Medicine
Open access |
23 Feb 2005 |
3,981 |
| 42 |
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo‐Jack, Alice Tsang Shaw · Nature Reviews Clinical Oncology
Review |
8 Nov 2017 |
3,967 |
| 43 |
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine
Open access |
4 Jun 2018 |
3,816 |
| 44 |
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Peter Goldstraw, John Crowley, Kari Chansky et al. · Journal of Thoracic Oncology
Open access |
Aug 2007 |
3,691 |
| 45 |
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
Harry J. de Koning et al. · New England Journal of Medicine
Open access |
29 Jan 2020 |
3,674 |
| 46 |
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia Van Dam Sequist et al. · Science Translational Medicine
Open access |
23 Mar 2011 |
3,603 |
| 47 |
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al. · Nature Medicine
Open access100 authors |
8 May 2017 |
3,585 |
| 48 |
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
William J. Pao, Vincent A. Miller, Katerina A. Politi et al. · PLoS Medicine
Open access |
17 Feb 2005 |
3,557 |
| 49 |
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Bruce D. Cheson, Sandra J. Horning, Bertr Coiffier et al. · Journal of Clinical Oncology
|
Apr 1999 |
3,495 |
| 50 |
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Alice Tsang Shaw et al. · New England Journal of Medicine
Open access |
Jun 2013 |
3,429 |